Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer

ABSTRACT: Interventions: Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles. Primary outcome(s): PFS Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced/recurrent Colorectal Cancer

PROVIDER: 2616805 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR